Table 1.
Clinical Characteristics of the Cohort
| Variables | Entire Cohort N = 30 |
O2 Pulse < 85% n = 16 |
O2 Pulse ≥85% n = 14 |
P-Value |
|---|---|---|---|---|
| Age, y | 63 [57–67] | 61 [54–64] | 64 [58–69] | 0.249 |
| Female | 18 (60%) | 7 (44%) | 10 (71%) | 0.076 |
| Race | 0.107 | |||
| Caucasian | 20 (67%) | 9 (56%) | 5 (36%) | |
| African-American | 10 (33%) | 7 (44%) | 2 (14%) | |
| Body Mass Index, kg/m2 | 27.1 [23.6–30.6] | 24.5 [20.8–27.2] | 30.3 [27.0–31.2] | 0.005 |
| Body Surface Area, m2 | 1.88 [1.73–1.99] | 1.81 [1.71–1.94] | 1.92 [1.79–2.14] | 0.132 |
| COPD | 18 (60%) | 13 (81%) | 5 (36%) | 0.023 |
| FACT-G7 score | 20.0 [15.0–23.5] | 17.5 [14.3–22.3] | 21.0 [18.0–25.0] | 0.041 |
| Cancer type | 0.008 | |||
| Lung or Other* | 20 (67%) | 14 (88%) | 5 (36%) | |
| Breast | 10 (33%) | 2 (13%) | 8 (57%) | |
| Other Malignancies | ||||
| Esophageal | 2 (7%) | |||
| Hodgkin’s Lymphoma | 1 (3%) | |||
| Desmoid Tumor | 1 (3%) | |||
| Castleman’s Disease | 1 (3%) | |||
| Time since Diagnosis, y | 2.6 [1.3–4.2] | 2.8 [1.4–7.0] | 2.4 [0.6–2.8] | 0.398 |
| Time since Radiotherapy, y | 2.0 [0.6–3.8] | 2.2 [0.8–5.8] | 2.2 [0.6–2.8] | 0.423 |
| Time since chemotherapy, y | 1.7 [0.5–2.9] | 1.5 [0.2–4.2] | 1.9 [0.6–2.8] | 0.423 |
| Prior Chemotherapy | 26 (87%) | 14 (88%) | 11 (79%) | 0.617 |
| CVD Risk Factors | ||||
| Hypertension | 17 (57%) | 8 (50%) | 8 (57%) | 0.404 |
| Diabetes Mellitus | 7 (23%) | 1 (6%) | 6 (43%) | 0.019 |
| Hypercholesterolemia | 14 (47%) | 8 (50%) | 6 (43%) | 0.566 |
| Current Smoker | 6 (20%) | 5 (31%) | 1 (7%) | 0.037 |
| Obesity | 10 (33%) | 3 (19%) | 7 (50%) | 0.064 |
| Beta-blocker Use | 5 (17%) | 2 (13%) | 3 (21%) | 0.396 |
| ACEI/ARB Use | 6 (20%) | 2 (13%) | 4 (29%) | 0.423 |
| NTproBNP, pg/mL | 187 [51–310] | 298 [89–445] | 72 [31–200] | 0.013 |
Data are listed as median and [interquartile range] or n (%). *Other malignancies grouped with lung cancer subjects. P-values are differences between groups (< 85% and ≥ 85% predicted peak exercise O2 Pulse)
Abbreviations: y years, COPD chronic obstructive pulmonary disease, FACT-G7 Functional Assessment of Cancer Therapy-General (7-item version), ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin receptor blocker, NTproBNP N-terminal pro-brain natriuretic peptide